Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax in Relapsed Classic or Variant Hairy Cell Leukemia
NCT06311227Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in hairy cell leukemia (HCL), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate. Started Dec 2024; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on NCT06311227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06311227.